Merus: FDA Extends Review of Cancer Drug Zenocutuzumab to February

Dow Jones11-05

By Colin Kellaher

Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment.

Merus said the FDA set a new target action date of Feb. 4 after the Utrecht, Netherlands, company submitted information in response to an agency request related to chemistry, manufacturing and controls.

Merus, which is seeking approval of zenocutuzumab in certain patients with non-small cell lung and pancreatic cancer, noted that the FDA didn't request any additional clinical data.

The FDA in May granted priority review, which typically entails a six-month review, to Merus's application for zenocutuzumab.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 05, 2024 08:17 ET (13:17 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481509873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481509873","market":"fut","top_or_hot":-1,"title":"Merus: FDA Extends Review of Cancer Drug Zenocutuzumab to February","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment. \n</p>\n<p>\n  Merus said the FDA set a new target action date of Feb. 4 after the Utrecht, Netherlands, company submitted information in response to an agency request related to chemistry, manufacturing and controls. \n</p>\n<p>\n  Merus, which is seeking approval of zenocutuzumab in certain patients with non-small cell lung and pancreatic cancer, noted that the FDA didn't request any additional clinical data. \n</p>\n<p>\n  The FDA in May granted priority review, which typically entails a six-month review, to Merus's application for zenocutuzumab. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2024 08:17 ET (13:17 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus: FDA Extends Review of Cancer Drug Zenocutuzumab to February</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus: FDA Extends Review of Cancer Drug Zenocutuzumab to February\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment. \n\n\n  Merus said ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481509873","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481509873","pubTimestamp":1730812620,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment.Merus said the FDA set a new target action date of Feb. 4 after the Utrecht, Netherlands, company submitted information in response to an agency request related to chemistry, manufacturing and controls.Merus, which is seeking approval of zenocutuzumab in certain patients with non-small cell lung and pancreatic cancer, noted that the FDA didn't request any additional clinical data.The FDA in May granted priority review, which typically entails a six-month review, to Merus's application for zenocutuzumab.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","MRUS":"Merus B.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Merus：FDA将抗癌药物Zenocutuzumab审查延长至2月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRUS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment. \n\n\n  Merus said the FDA set a new target action date of Feb. 4 after the Utrecht, Netherlands, company submitted information in response to an agency request related to chemistry, manufacturing and controls. \n\n\n  Merus, which is seeking approval of zenocutuzumab in certain patients with non-small cell lung and pancreatic cancer, noted that the FDA didn't request any additional clinical data. \n\n\n  The FDA in May granted priority review, which typically entails a six-month review, to Merus's application for zenocutuzumab. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2024 08:17 ET (13:17 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481509873"}